KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) Revenue (2017 - 2025)

Cardlytics (CDLX) has disclosed Revenue for 9 consecutive years, with $56.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 24.19% year-over-year to $56.1 million, compared with a TTM value of $233.3 million through Dec 2025, down 16.18%, and an annual FY2025 reading of $233.3 million, down 16.18% over the prior year.
  • Revenue was $56.1 million for Q4 2025 at Cardlytics, up from $52.0 million in the prior quarter.
  • Across five years, Revenue topped out at $90.0 million in Q4 2021 and bottomed at $52.0 million in Q3 2025.
  • Average Revenue over 5 years is $69.3 million, with a median of $67.8 million recorded in 2022.
  • The sharpest move saw Revenue soared 108.54% in 2021, then dropped 24.19% in 2025.
  • Year by year, Revenue stood at $90.0 million in 2021, then dropped by 8.38% to $82.5 million in 2022, then grew by 8.08% to $89.2 million in 2023, then decreased by 17.01% to $74.0 million in 2024, then fell by 24.19% to $56.1 million in 2025.
  • Business Quant data shows Revenue for CDLX at $56.1 million in Q4 2025, $52.0 million in Q3 2025, and $63.2 million in Q2 2025.